EMEA suspends Hexavac
The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation of multiple disease vaccine Hexavac, because of concerns about its long-term protection against hepatitis B.
The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation of multiple disease vaccine Hexavac, because of concerns about its long-term protection against hepatitis B.
The drug is administered to infants and children and also protects (successfully) against diphtheria, tetanus, whooping cough, polio and haemophilus influenzae type b.
EMEA's human medicines committee has asked manufacturer Sanofi Pasteur MSD to investigate whether Hexavac vaccinated children might need revaccination against hepatitis B, maybe during adolescence.